American Association for the Advancement of Science, Science Translational Medicine, 411(9), 2017
DOI: 10.1126/scitranslmed.aan2514
Full text: Unavailable
IL-36 receptor (IL-36R) blockade ameliorates psoriatic inflammation and should be well tolerated, because IL-36R knockout mutations are benign.